Adaptive Biotechnologies Corporation
NASDAQ:ADPTBiotechnology
+$0.61 today
- Market cap
- $4.61B
- Beta
- 2.15
- P/E (TTM)
- -54.5
- EPS (TTM)
- -$0.32
Volume 2.21M
Average 1.94M
ADPT Total Current Liabilities
All obligations due within one year.
Adaptive Biotechnologies CorporationNASDAQ: ADPT
Total Current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total current liabilities falls 4.8% from a year ago
Total current liabilities stood at $87.71M at the end of Q2 FY2026, down 4.8% from a year earlier and up 0.8% from the prior quarter. Over 3 fiscal years it compounded at -6.4% a year.
Context
- Total current liabilities amounted to 13.7% of total assets at the end of Q2 FY2026, down 4.9 pp from a year earlier.
- Total current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -4.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 89.92M USD
- Year-over-year change
- -8.3%
- 4-year CAGR
- -5.7%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 89.92M | -8.3% |
| FY2024 | 2024-12-31 | 98.05M | +11.4% |
| FY2023 | 2023-12-31 | 88.02M | -19.8% |
| FY2022 | 2022-12-31 | 109.79M | -3.5% |
| FY2021 | 2021-12-31 | 113.81M | — |
Total Current Liabilities vs competitors
How ADPT compares with its peers on the latest reported figures
- ADPT's Jun 2026 total current liabilities of $87.71M is the 5th highest of the 10 companies compared; the peer median is $80.88M.
- Its year-over-year change of -4.8% is the 7th highest of 10, against a peer median of +27.5%.
- Total current liabilities amounts to 13.7% of total assets for ADPT, versus a peer median of 11.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $428.58M | +29.3% | +43.8% | 39.9% | |
| Sep 2026 | $289.6M | -33.2% | +28.8% | 17.2% | |
| Sep 2026 | $227.11M | +94.0% | +106.4% | 44.9% | |
| Mar 2026 | $132.4M | +18.6% | +36.7% | 11.5% | |
| Jun 2026 | $87.71M | -4.8% | -6.4% | 13.7% | |
| Jun 2026 | $80.88M | -53.6% | -24.3% | 5.8% | |
| Sep 2026 | $80.12M | +29.3% | +15.1% | 18.0% | |
| Mar 2026 | $64.83M | +27.5% | +22.9% | 6.3% | |
IRONDisc Medicine, Inc. | Sep 2026 | $34.36M | +28.5% | +17.5% | 4.9% |
| Jun 2026 | $19.32M | -12.9% | +23.3% | 2.9% | |
| Peer median (excluding ADPT) | $80.88M | +27.5% | +23.3% | 11.5% | |
Competitors are the stored peer set for ADPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 139.07M | 90.03M | 65.06M | 47.92M | 70.5M |
| Short-term Investments | 214M | 408.17M | 281.34M | 174.37M | 156.49M |
| Net Receivables | 17.41M | 40.06M | 37.97M | 41.73M | 50.37M |
| Inventory | 19.26M | 14.45M | 14.45M | 8.44M | 9.82M |
| Other Current Assets | 0 | 9.44M | 11.37M | 11.29M | 13.02M |
| Total Current Assets | 402.75M | 562.15M | 410.19M | 283.75M | 300.19M |
| Property, Plant & Equipment (Net) | 172.94M | 164.21M | 120.32M | 94.38M | 74.72M |
| Goodwill | 118.97M | 118.97M | 118.97M | 118.97M | 118.97M |
| Intangible Assets | 8.53M | 6.83M | 5.13M | 3.43M | 1.73M |
| Long-term Investments | 217.15M | 0 | 0 | 33.66M | 15.92M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.01M | 4.46M | 6.52M | 5.18M | 1.21M |
| Total Non-current Assets | 520.6M | 294.47M | 250.95M | 255.62M | 212.55M |
| Total Assets | 923.34M | 856.62M | 661.13M | 539.38M | 512.74M |
| Account Payables | 3.31M | 8.08M | 7.72M | 7.27M | 6.47M |
| Short-term Debt | 0 | 0 | 0 | 0 | 13.56M |
| Tax Payables | 391K | 194K | 59K | 176K | 0 |
| Deferred Revenue | 80.46M | 64.12M | 48.63M | 55.69M | 45.19M |
| Other Current Liabilities | 15.64M | 15.94M | 13.69M | 16.7M | 7.7M |
| Total Current Liabilities | 113.81M | 109.79M | 88.02M | 98.05M | 89.92M |
| Long-term Debt | 0 | 0 | 0 | 0 | 196.79M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 98.75M | 58.6M | 44.79M | 27.26M | 1.01M |
| Other Non-current Liabilities | 0 | 125.36M | 130.66M | 132.43M | (70.21M) |
| Total Non-current Liabilities | 205.44M | 282.73M | 264.84M | 238.84M | 197.82M |
| Total Liabilities | 319.24M | 392.52M | 352.86M | 336.89M | 287.74M |
| Common Stock | 14K | 14K | 14K | 14K | 15K |
| Retained Earnings | (718.89M) | (919.08M) | (1.14B) | (1.3B) | (1.36B) |
| Accumulated OCI | (1.14M) | (4.12M) | 215K | 166K | 253K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 110K | (67K) | (121K) | (224K) | 6.21M |
| Total Equity | 604.1M | 464.1M | 308.28M | 202.49M | 225M |
| Total Debt | 111.74M | 108M | 98.77M | 89.39M | 280.58M |
| Net Debt | (27.33M) | 17.97M | 33.71M | 41.47M | 210.09M |
Adaptive Biotechnologies Corporation
NASDAQ:ADPT
Intrinsic Alpha fair value
Locked
Current Price
$28.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.